Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company ...

Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The IPO comes just a few weeks after Caris raised $168 million in a private financing round that took the total raised by the ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Iran and Israel's air war, which began on Friday when Israel attacked Iran's nuclear facilities, has raised concerns that the ...